Anti D 300mcg 1ml Injection

Anti D 300mcg/ml Injection is an important immunoglobulin therapy aimed at preventing Rh sensitization. It is critical for Rh-negative expectant mothers to receive for the sake of their Rh-positive children. It also benefits Rh-negative patients who receive Rh-positive blood transfusions as well as patients with immune thrombocytopenic purpura (ITP). This medicine is given as an intramuscular injection to the patients. It is given to patients by healthcare providers only as a preventive measure to avert dangerous hemolytic conditions in prospective pregnancies.

Key Benefits

• Assists in avoiding complications linked to Rh incompatibility during pregnancy.
• Decreases chances of hemolytic disease in infants.
• Assists in the management of immune thrombocytopenic purpura (ITP).
• Advised after transfusion complications for Rh-negative patients.
• Administered by a qualified medical practitioner to avoid misuse.
• Offers continued protection in subsequent pregnancies for Rh-negative women.

Each dose of AntiD 300 mcg/ml Injection contains 300 micrograms of Rho (D) immunoglobulin derived from human plasma formulated in a preservative-free solution. Immunoglobulin neutralizes Rh-positive red blood cells, preventing an immune response in Rh-negative individuals.

This is an intramuscular injection (site of administration for this drug is muscle; most administered to deltoid muscle i.e. upper arm).

Step 1: Locate & Clean 2-inch area around the site with alcohol swab or pad.
Step 2: Prepare and plunge-in the drug into syringe from the vial.
Step 3: Insert the needle & plunge-out at a 90° angle to the skin with a quick thrust.
Step 4: Withdraw the needle at the same angle & press a cotton ball over site.

NOTE: Do not self-administer. It is intended to be used by healthcare professionals only.

• Any allergic reactions or injection site discomfort should be reported immediately.
• Contraindications include bleeding disorders and immune system conditions.
• Avoid use if you have had previous severe immunological reactions.
• Monitoring patients post-administration is advisable to prevent risks.